Sign Up to like & get
recommendations!
0
Published in 2018 at "European Journal of Pain"
DOI: 10.1002/ejp.1192
Abstract: Antiepileptic drugs are the first‐line treatment for trigeminal neuralgia (TN). Carbamazepine and oxcarbazepine are the most studied with well‐known efficacy. Eslicarbazepine acetate is a third‐generation antiepileptic drug that has not previously been evaluated for the…
read more here.
Keywords:
treatment;
treatment trigeminal;
efficacy;
safety eslicarbazepine ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Journal of Neurology"
DOI: 10.1007/s00415-017-8618-5
Abstract: The Euro-Esli study was an exploratory pooled analysis of data from 14 European clinical practice studies, which was conducted to audit the real-world effectiveness, safety, and tolerability of eslicarbazepine acetate (ESL) as an adjunctive treatment…
read more here.
Keywords:
real world;
audit real;
treatment;
safety ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "CNS Drugs"
DOI: 10.1007/s40263-018-0504-x
Abstract: BackgroundIn the treatment of pediatric epilepsy, there is a critical demand for effective and safe therapeutic options to address patients’ unmet clinical needs. Eslicarbazepine acetate is a novel once-daily antiepileptic drug and a third-generation single…
read more here.
Keywords:
treatment;
acetate;
risk ratio;
eslicarbazepine acetate ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Epilepsy Research"
DOI: 10.1016/j.eplepsyres.2017.10.018
Abstract: OBJECTIVE Evaluate if eslicarbazepine acetate (ESL) in combination with other non-inducer antiepileptic drugs (AEDs) in the treatment of epilepsy may represent a positive impact in the cardiovascular risk profile. METHODS multicentre, retrospective, observational, non-interventional, real-life…
read more here.
Keywords:
inducer;
intima media;
eslicarbazepine acetate;
media thickness ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2017 at "Acta Neurologica Scandinavica"
DOI: 10.1111/ane.12734
Abstract: To assess seizure control and tolerability of eslicarbazepine acetate (ESL) as adjunctive therapy to one baseline antiepileptic drug (AED), in adults with partial‐onset seizures (POS) with or without secondary generalization.
read more here.
Keywords:
therapy clinical;
eslicarbazepine acetate;
adjunctive therapy;
acetate adjunctive ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2018 at "Epilepsia"
DOI: 10.1111/epi.13993
Abstract: We assessed the efficacy and safety of once‐daily eslicarbazepine acetate in comparison with twice‐daily (BID) controlled‐release carbamazepine (carbamazepine‐CR) monotherapy in newly diagnosed focal epilepsy patients.
read more here.
Keywords:
carbamazepine;
controlled release;
efficacy safety;
release carbamazepine ... See more keywords
Sign Up to like & get
recommendations!
1
Published in 2022 at "Drug Design, Development and Therapy"
DOI: 10.2147/dddt.s392934
Abstract: Purpose The present study aimed to establish and validate an isotope-dilution-UHPLC-MS/MS method for the determination of perampanel (PER) concentration and investigate the effect of eslicarbazepine acetate (ESL) on the pharmacokinetics of PER in rats. Methods…
read more here.
Keywords:
dilution uhplc;
eslicarbazepine acetate;
isotope dilution;
effect eslicarbazepine ... See more keywords
Sign Up to like & get
recommendations!
0
Published in 2021 at "Revista de neurologia"
DOI: 10.33588/rn.7208.2020593
Abstract: INTRODUCTION Eslicarbazepine acetate is a novel sodium channel blocker for use in the treatment of focal onset seizures. Prospective studies on its effectiveness in monotherapy in patients with newly diagnosed partial epilepsy in routine clinical…
read more here.
Keywords:
epilepsy;
patients newly;
newly diagnosed;
monotherapy patients ... See more keywords